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Abstract Currently there are no curative therapies
available for patients with metastatic prostate cancer.
Thus, novel therapies are needed to treat this patient
population. Immunotherapy represents one promising
approach for the elimination of occult metastatic tumors.
However, the prostate tumor microenvironment (TME)
represents a hostile environment capable of suppressing
anti-tumor immunity and effector cell function. In view
of this immunosuppressive activity, we engineered
murine prostate cancer cells with regulated expression
(tet-on) of CCL21. Prostate tumor cells implanted
orthotopically produced primary prostate tumors with
predictable metastatic disease in draining lymph nodes
and distant organs. Expression of CCL21 in the prostate
TME enhanced survival, inhibited tumor growth and
decreased the frequency of local (draining lymph node)
and distant metastasis. Therefore, these studies provide a
strong rationale for further evaluation of CCL21 in
tumor immunity and its use in cancer immunotherapy.
Keywords Tumormicroenvironment.CCL21.Prostate
cancer.TRAMP.T-RExsystem.Cancerimmunosupression
Abbreviations
DC Dendritic cell
TME Tumor microenvironment
TRAMP Transgenic adenocarcinoma of mouse prostate
cancer
TCR T cell receptor
Dox Doxycycline
Tet Tetracycline
TILs Tumor infiltrating Leukocyctes
TR Tet repressor
(flt-3-L) Fms-like tyrosine kinase 3 ligand
(SCID) severe combined immunodeficiency
Introduction
Prostate cancer is the most diagnosed cancer and the second
leading cause of mortality from cancer among American men
[1]. Surgery, hormone therapy and radiation therapy remain
the treatments of choice for the early (localized) stages of
prostate cancer. Despite these treatments a significant
population of men have recurrent disease suggesting the
presence of occult tumors in this patient group. There is
currently no effective treatment for these patients with
recurrent metastatic disease. In that regard, immunotherapy
represents a novel and promising approach that has the
potential to identify and destroy occult tumor cells.
CCL21 (secondary lymphoid tissue chemokine, exodus-
2, 6Ckine) has been known as a lymphoid chemokine that
is mainly and constitutively expressed by lymphatic
vessels, stromal cells in the spleen and appendix, and by
high endothelial venules in lymph nodes and Peyer’s
patches [2, 3]. CCL21 binds to the chemokine receptor
CCR7 and is chemoattractant for mature DCs, naive and
memory T cells [4, 5]. This chemokine as well as CCL19
are also necessary for normal lymphoid tissue organization
that is essential for effective T cell-dendritic cell interac-
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strating CCL21-treansfected Hepal-6 liver tumors were
infiltrated with T cells and DCs and formed a new
lymphoid-like tissue within the tumor mass [6]. Further-
more, expression of CCL21 in transgenic mice with islet β-
cell-specific expression of CCL21 has been shown to
trigger formation of lymphoid-like tissue in the pancreatic
islets by recruiting T lymphocytes and DCs to this tissue
[7]. Thus, these results suggest that local expression of
CCL21 in the TME can co-localize essential immune cells
necessary for promoting an anti-tumor immune response
and tumor rejection. Although both CCL21 and CCL19 are
chemattractants for T cells and DCs, CCL21 can also
inhibit tumor growth independent of leukocyte recruitment
because it possesses angiostatic activity [8]. For this reason
we asssed the anti-tumor activity of CCL21 when secreted
in the prostate tumor microenvironment.
In this study we used TRAMPC2 (transgenic adenocar-
cinoma of mouse prostate), a well-characterized orthotopic
mouse prostate model to access the impact of the prostate
tumor microenvironment (TME) on infiltrating DCs and T
cells. TRAMPC2 tumor cells produce primary tumors with
reproducible and predictable metastasis to draining peri-
aortic lymph nodes in all mice and to distant organs in a
subset of cohorts [9, 10]. TRAMPC2 tumors are heavily
infiltrated with myeloid but not lymphoid (T and B) cells
that seem to be responsible for disruption of the CD3/TCR
signaling complex [11, 12]. In this study we modified the
TME by inducing secretion of CCL21 from transfected
TRAMPC2 to promote infiltration of DCs and T cells with
minimal infiltration of myeloid cells. Expression of CCL21
was put under control of the tetracycline (tet-on) regulated
expression system so that chemokine expression could be
induced at specific times during tumor progression. The
data presented herein suggests that local expression of
CCL21 in the tumor bed represents a promising approach to
induce immune-mediated regression of malignant tumors.
Material and Methods
CCL21 Gene Expression Plasmid
The tetracycline regulated CCL21 expression vector was
obtained by inserting the PCR amplified mouse CCL21
gene into the tet-on expression vector from Invitrogen
(Carlsbad, CA). The vector-containing mouse CCL21
open reading frame was purchased from Invivogen (San
Diego, CA). The CCL21 gene was PCR amplified with
forward primer 5’-GCG CGG GAT CCC ATG GCT
CAG ATG ATG AC-3’ and reverse primer 5’-TCA TGT
CGA GCT AGC GGG CTC CAG GCG-3’ using
PfuTurbo DNA polymerase (Stratagene, La Jolla, CA).
A BamHI site (GGATCC) was inserted into the forward
primer to be used for ligation to the expression vector.
Amplified CCL21 gene was digested with BamHI and
NheI and ligated into the T-REx expression vector
digested with BamHI and XbaI. The integrity of the
CCL21 expression plasmid (pcDNA4/TO/CCL21) was
confirmed by sequencing.
Tumor Cell Lines, Manipulations and Implantation
TRAMPC2 cells were established from a prostate tumor
from a TRAMP mouse and were kindly provided by
Norman Greenberg (Baylor College of Medicine, Houston,
TX). To generate stably transfected cell lines, TRAMPC2
cells were transfected with the T-REx repressor (TR) and
pcDNA4/TO/CCL21 expression vectors (Invitrogen, Carls-
bad, CA) using Fugene6 (Roche Applied Science, Indian-
apolis, IN) following the manufacturer’s protocol. Cells
were maintained in antibiotic containing media for at least 3
weeks before testing for tetracycline inducible expression
of CCL21 by ELISA. Briefly 1x10
5 cells from each clone
were seeded in 12 well plates containing 1ml of media in
duplicate. The following day the media was replaced with
fresh media with or without 2mg/ml of tetracycline
(Invitrogen, Carlsbad, CA). The assay was performed on
the third day based on the manufacturer’s protocol (R and
D system, Minneapolis, MN).
To establish an orthotopic tumor, mice prostate
glands were surgically exposed and injected with
0.05ml of media containing 5x10
5 tumor cells. Mice
were regularly monitored for tumor growth. Mice were
treated with 0.02mg/ml of doxycycline (a tetracycline
derivative) along with 0.5% sucrose in their drinking water
when indicated. All animal protocols were conducted in
accordance with National Institute of Health guidelines
and were reviewed and approved by the Institutional
Animal Care and Use Committee of Eastern Virginia
Medical School. Tumor infiltrating leukocytes (TILs) were
isolated from palpable tumors that were excised, diced and
digested enzymatically as previously reported [13]. Cells
were then washed to remove enzymes and dead cells were
eliminated from the preparation by Ficoll (Isolymph,
Gallard-Schlesinger Industries, Carle Place, NY) gradient
centrifugation [11]. Single cell suspension of spleens from
normal mice and tumor bearing mice were prepared
following the procedure for TILs and used as control. To
detect metastatic disease in mice with TRAMP tumors,
different tissues (lymph nodes, lungs, pancreas and bone
marrow) were harvested aseptically and cultured as
described previously [14]. In some cases prostate tumors
were cultured using the same technique and cells from
explanted outgrowths were expanded for re-injection into
t h ep r o s t a t eg l a n d .
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Multiparameter flow cytometric analysis was performed as
previously reported [15]. Antibodies used in this study were
obtained from eBioscience (San Diego, CA). DNA content
of cell lines derived from metastatic loci was determined by
staining the cells with propidium iodide (PI, Sigma, St.
Louis, MO) and analyzed on a BD FACScan cytometer as
previously described [14].
Results
DCs Infiltrating TRAMPC2 Tumors are Phenotypically
Immature
TRAMPC2 tumors grow progressively in immune compe-
tent mice suggesting that these cells induce a weak or
inefficient anti-tumor immune response. This may reflect
the ability of the TRAMPC2 TME to impair DC (CD11c+
cells) function. CD11c has been used here to identify DCs,
although it can also be expressed by activated T and B cells
as well as natural killer (NK) cells. However, intratumoral
T cells remain quiescent in the TRAMP TME because they
do not express the activation antigens CD25 or CD69 (data
not shown). Furthermore, T and B cells are not a major
infiltrating cell types in TRAMP tumors. NK cells are
typically not detected in TRAMP TILs or are present as a
trace population and therefore do not contribute signifi-
cantly to CD11c expression in the TRAMP TME. We
observed that the majority of DCs infiltrating TRAMPC2
tumors failed to express normal levels of class II antigens
(IA
b), B7.2 and CD40 molecules compared to their
counterparts isolated from either normal or tumor bearing
spleens (Fig. 1-b). Most of the infiltrating DCs appeared to
be myeloid in origin because they did not express CD8α
(B-g, h and i and C). Class I antigen (H2D
b) expression was
not suppressed by the TME as equivalent levels of
expression were observed on intratumoral and splenic
DCs (Fig. 1-b; g, h and i). Surprisingly, CD86 expression,
but not CD80, was suppressed suggesting differential
regulation of B7 family members within the prostate TME
(Fig. 1-c). As expected, expression of the chemokine
receptor CCR7 was down-regulated relative to normal
spleen (Fig. 1-c). In contrast, DC expression of PDL2
shown to inhibit the activation and cytokine production of
CD4
+ T cells [16] was elevated on intratumoral DCs
relative to normal splenic DCs (Fig. 1-c). Thus, these data
Fig. 1 Dendritic cells isolated from prostate tumors display an
immature phenotype. Mice were transplanted orthotopically with
TRAMPC2 tumor cells and 30 days later excised when tumor mass
reached approximately 1 cm in diameter. Single cell suspension from
normal and tumor bearing (TB) spleens were prepared and TILs
isolated from TRAMPC2 tumors. Cells were stained with indicated
mAbs and evaluated by 4-color flow cytometry. a Single color
analysis (forward scatter vs. log fluorescent intensity) of CD11c
+ cells
of normal spleen and TILs isolated from TRAMPC2 tumors. The R1
region was set based on the appropriate isotype matched control. The
background for isotype matched control was 0.07% for splenocytes
and 0.04% for TILs. b Expression of the indicated cell surface
molecules on gated CD11c
+ cells. Values in each quadrant indicate the
percentage of cells in the CD11c
+ gate that stained with the indicated
mAbs. c Further phenotypic characterization of splenic and tumor
associated DCs displayed as bar graphs. Data are representative of 3
independent experiments with 3 mice/ group in each experiment
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they fail to express a number of cell surface markers
associated with DC maturation.
Characterization of TRAMPC2 Cells with Regulated
Expression of CCL21
Previous studies showed that the presence of CCL21 in
tumors promotes the infiltration of DCs and T cells that
enhanced the anti-tumor immune response and inhibited
tumor growth [6, 17]. We examined whether direct intra-
tumoral expression of CCL21 via gene-modified
TRAMPC2 cells would inhibit tumor growth and metastatic
disease in this model. We therefore transfected TRAMPC2
cells with both the repressor and CCL21 tet-inducible
expression vectors. Six antibiotic resistant TRAMPC2/TR/
CCL21 clones were isolated that possessed low constitutive
expression of the chemokine and 12-to 60-fold induction of
CCL21 in the presence of tetracycline. Three out of 6 lines
maintained the tet-inducible expression of CCL21 (termed
TRAMPC2/TR/CCL21) after 3 and 8 additional passages
although clone 6 had lower levels of inducible expression
after 8 passages (Fig. 2-a). To establish a cell line that
grows and maintains regulated expression of CCL21 in
vivo, TRAMPC2/TR/CCL21 tumor cells (Fig. 2a, clone 4)
were implanted into the prostate gland of nine mice. One
mouse died without evidence of a palpable prostate tumor.
Six mice developed palpable tumors that were excised and
clonal outgrowths were obtained without selection anti-
biotics. Outgrowths from two tumors (M5, M6) were no
longer tet-inducible and were not further studied (Table 1).
Seventy clonal lines were obtained from the remaining four
tumors of which ten were inducible for CCL21 expression
(Fig. 2b and Table 1). Clonal outgrowths derived from
mouse 1 (M1) generally had low constitutive CCL21 levels
with relatively weak induction for CCL21. The remaining
clones demonstrated higher tet-induced CCL21 secretion
Fig. 2 Variable expression of CCL21 by TRAMPC2/TR/CCL21 cells
following passage in vitro and tumor growth in vivo. a TRAMPC2
cells were transfected with the repressor and CCL21 expression
vectors using Fugene 6 transfection reagent and selected in antibiotic-
containing media. Cloned antibiotic resistant cell lines (TRAMPC2/
TR/CCL21, clones 4, 5 and 6) were tested for CCL21 expression with
or without 2 ug/ml of tetracycline by ELISA. ELISA was performed
after 3 and 8 passages to test whether these clones maintained
inducible expression of the transgene. b Syngeneic mice were
implanted orthotopically with TRAMPC2/TR/CCL21 tumor cells
(clone 4, 5×10
5). After several months following implantation,
palpable tumors were excised, diced and explants cultured in vitro.
Cloned lines were derived, expanded in selection media and tested for
tet-induced secretion of CCL21. Clonal lines from six tumors isolated
from individual mice (M1-6) were evaluated (see Table I). This panel
illustrates the expression levels achieved by tetracycline in the 10
clones (10/103) that produced CCL21. None of the lines derived from
two tumors (M5 and M6) displayed inducible expression of CCL21. c
Eight clonal lines with weak induction derived from mouse tumors 1
and 4 were pooled to generate L1. The remaining two lines (M3.2 and
M4.2) were pooled to generate L2. These two pooled lines were then
subjected to antibiotic selection using zeocin and blasticidin, expanded
in vitro and then tested for inducible CCL21 production. Note
different scales in panels B and C
Table 1 Distribution of inducible expression of CCL21 in clonal lines
derived from TRAMC2/TR/CCl21 tumors following orthotopic tumor
growth in vivo
Mouse No.
Clones
No. Inducible
Clones
% Inducible
Expression
M1 22 6 27
M2 18 1 5.5
M3 19 1 5.3
M4 11 2 18
M5 15 0 0
M6 18 0 0
Total 103 10 9.7
Nine syngeneic mice were implanted orthotopically with TRAMPC2/
TR/CCL21 tumor cells (5×10
5). One mouse died without any tumor
and two mice never grew tumors. After several months following
implantation, 6 palpable tumors were excised, diced and explants
cultured in vitro. Cloned lines were derived, expanded in selection
media and tested for tet-induced secretion of CCL21 by ELISA.
Clonal lines from six tumors isolated from individual mice were
evaluated (M1-6).
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clonal outgrowths from intraprostatic tumors were isolated
and grown in the absence of selection media, the relatively
modest induction of CCL21 production may indicate that
TRAMPC2/TR/CCL21 tumor cells lost or silenced the
CCL21 gene during in vivo growth. To test this hypothesis
and to enrich for tumor cells with stable tet-inducible
expression of CCL21, the 8 weakly inducible clonal lines
from mouse 1 (M1.1-1.19) and 4 (M4.2, M4.4) were pooled
to generate TRAMPC2/TR/CCL21-L1. The remaining two
lines were also pooled to produce TRAMPC2/TR/CCL21-
L2. Both populations were then subjected to antibiotic
selection. Fig. 2c demonstrates that growth in selection
media enhanced CCL21 production by TRAMPC2/TR/
CCL21-L1 cells (Line 1) approximately 5-fold without
increasing constitutive CCL21 levels. Although
TRAMPC2/TR/CCL21-L2 (Line 2) cells had higher back-
ground expression relative to Line 1, tetracycline induced
much higher levels of CCL21 production. These data
indicate that both these lines have the capacity to grow
both in vitro and in vivo following orthotopic implantation.
Impact of Intratumoral Expression of CCL21 on Survival,
Tumor Growth and Metastatic Disease
TRAMPC2/TR/CCL21 clones (L1 and L2) displayed high
levels of tet-inducible expression of CCL21 and grew in
vivo. We next wanted to test whether CCL21 expression in
the TME enhances survival of mice implanted orthotopi-
cally with prostate tumor cells. Therefore, mice were
randomly divided into two groups and one group received
doxycycline in their drinking water starting the day after
surgical implantation of TRAMPC2/TR/CCL21-L2. Mice
were sacrificed and tumors explanted for in vitro growth
when mice showed signs of morbidity. As demonstrated in
Fig. 3a (left panel), prolonged survival was observed in
doxycycline-treated mice. Control mice all died by day 32,
whereas, doxycycline treated mice lived up to 50 days post
implantation. Low levels of CCL21 were detected in the
serum of 25% of tumor bearing mice treated with
doxycycline and was not detected in the serum of control
mice. Analysis of clonal lines derived these tumors
demonstrated that <10% were capable of inducible expres-
sion of CCL21 (right panel). All these cell lines eventually
lost inducible expression after a few in vitro passages (data
not shown). Thus, tumor growth in vivo was associated
with loss of inducible expression of CCL21. This may have
contributed to the limited growth inhibition and eventual
outgrowth of primary prostate tumors observed in these
mice.
To determine whether prolonged survival induced by
intratumoral CCL21 expression reflected inhibition of
primary tumor growth and/or inhibition of metastatic
disease, we implanted TRAMPC2/TR/CCL21-L2 ortho-
topically into the total of 18 animals in two separate
experiments (8 and 10 mice, respectively). In each
experiment the mice were divided into two groups with
one group receiving doxycycline in their drinking water one
day after tumor implantation. Mice were sacrificed when
moribund and tumors, draining lymph nodes, lungs and
pancreases removed for measurements and assessment of
metastatic disease. One of the mice given doxycycline in
the first experiment and two from the control group in the
second experiment died shortly after tumor implantation
and therefore were excluded from this analysis. Tumors
grew in all mice irrespective of whether they received
doxycycline in their drinking water. However, Fig. 3b
demonstrates that tumors excised from doxycycline-treated
mice weighed less (left panel) and were smaller in size
(right panel) than tumors excised from control animals. As
expected, all control mice had metastases in draining
periaortic lymph nodes as well as metastases in their lung
in the majority of mice. A smaller subset also had
disseminated disease to the pancreas (panel C). In contrast,
treated mice had reduced frequency of metastasis to lymph
nodes and lungs with no metastases to the pancreas. These
data suggest that even limited and transient expression of
CCL21 in TRAMP TME suppresses primary tumor growth
as well as metastatic disease to draining lymph nodes and
distant organs.
In vivo Tumor Growth is Associated with Methylation
of CMV Promoter
The data presented above demonstrated that the vast
majority of TRAMPC2/TR/CCL21 tumor cells no longer
displayed inducible CCL21 induction following orthotopic
implantation. Two possibilities mechanisms were next
considered to explain this observation: loss of the transgene
or alternatively, silencing of the promoter. To test the first
possibility DNA was extracted from TRAMPC2/TR/
CCL21-L2 tumor pieces and cloned lines isolated and
expanded to generate sufficient DNA for PCR analysis
using specific primers to amplify the transfected CCL21
gene. It is apparent from Fig. 4 (panel A) that outgrowths
obtained from orthotopic TRAMPC2/TR/CCL21 tumors
still contained the CCL21 transgene. The absence of a
product in the control mouse DNA confirmed that the
primers did not amplify endogenous CCL21 gene (lane 9).
To test the possibility that the promoter was silenced by
methylation, we evaluated the methylation pattern of the
CMV promoter. DNA isolated from tumor pieces or clonal
lines were bisulfite treated and PCR reactions were
performed using primers complementary to a region of
CMV promoter not containing methylation sites (oligos 1)
or a pair of primers complementary to a region of CMV
Inhibition of prostate tumor growth by expression of CCL21 63promoter which contains methylation sites (oligos 2). If the
promoter is not methylated, a PCR product forms with both
primers, whereas, a single product is only detected with
oligos 1 if the promoter is methylated [18]. Fig. 4b
demonstrates that when the pcDNA4/TO/CCL21 plasmid
was tested following bisulfite conversion, PCR reactions
with both primers produced a product indicating that the
original plasmid DNA was not methylated. In contrast,
when DNA was extracted from two excised TRAMPC2/
CCL21-L2 tumors (M1 and M2, Fig. 3a), both promoters
appeared to be methylated, however, when a clonal
outgrowth derived from tumor M1 was tested, PCR
products formed with both primers suggesting that the
section of tumor excised for clonal expansion had a
functional promoter (not methylated). These data indicate
that during tumor growth in the prostate gland, the
promoter is variably methylated. Thus, in some sections
of the tumor, the promoter may still be functional. This may
explain why we detected some low-grade induction of
CCL21 in some clonal lines derived from explants of
TRAMPC2/TR/CCL21-L2 tumors (Fig. 3a, right panel).
Discussion
In this report we showed that TRAMP tumors were
infiltrated with small population of DCs. Although expres-
sion of CD11c on intratumoral DCs was low relative to
Fig. 3 Intraprostatic secretion of CCL21 prolongs survival, delays
tumor growth and reduces the frequency of metastatic disease. a Eight
mice (M1-8) were transplanted orthotopically with TRAMPC2/TR/
CCL21-L2 cells. Four mice were given doxycycline in their drinking
water one day after implantation. Mice were euthanized when tumors
were palpable or when mice were moribund. Tumors from treated and
control mice were excised, diced and cultured in tissue culture media
containing antibiotics. Derived clonal lines (M1.2, M2.10, etc.) were
then evaluated for inducible expression of CCL21. Enhanced survival
(left panel) was correlated with induced expression of CCL21 in the
prostate TME (right panel). The survival of treated mice was
significantly prolonged relative to non-treated mice (P<0.05). The
boxed ratios represent the number of cell lines isolated with inducible
CCL21 expression versus the total number of evaluated cell lines and
the cell line with the highest expression of CCL21 has been shown if
there were more than one cell lines expressing CCL21. b Mice (total
of 18, two separate experiments) were given an orthotopic injection of
5×10
5 TRAMPC2/TR/CCL21-L2 cells. One cohort was given
doxycycline in their drinking water after surgery and one group
served as control. Tumor growth was monitored by palpation and
approximately 2 months after implantation when the control mice
were morbid, tumors were excised. Weight (left panel) and volume
(right panel) of the tumors was then measured. c Lymph nodes, lungs
and pancreases of mice from one of the experiments described in
panel B were also removed, diced and cultured as described
previously. Tumor cells grew out of the organs with metastases and
generated cell lines that were expanded in vitro. Aneuploid DNA
content validated that the outgrowths represented TRAMPC2/TR/
CCL21 tumor cells [12]
64 N. Yousefieh et al.splenic DCs, it still exceeded the isotype control (Fig. 1).
We also demonstrated that DCs infiltrating TRAMPC2
tumors had low levels of MHCII, B7.2 and CD40
expression compared to their normal splenic counterparts.
Most of the intratumoral DCs were myeloid-derived
because they displayed a CD8α
− phenotype. In addition
to DC infiltrate, TRAMP tumors were infiltrated primarily
by macrophages and immature (Gr-1
+) myeloid cells but
few T and B cells. Because myeloid cells have been shown
to be immunosuppressive in several tumor models [19, 20],
we transfected TRAMPC2 tumors with CCL21, a chemo-
attractant for DCs and T cells. We speculated that inducible
expression of this chemokine should promote DC and Tcell
infiltration and promote anti-tumor immunity and tumor
rejection. To test this paradigm we generated transfected
TRAMPC2 tumors cells with inducible expression of
CCL21 so that we could regulate chemokine production at
discrete times during tumor growth. We isolated several
lines with stable and inducible expression of CCL21 in
vitro and derived two cell lines that also grew reproducibly
in mouse prostate glands. Mice implanted orthotopically
with one of these lines (TRAMPC2/TR/CCL21-L2) and
treated with doxycycline had reduced primary tumor
growth, decreased frequencies of metastatic disease and
enhanced survival. The inability of CCL21 to cure mice of
prostate tumors may have been related to low levels of
CCL21 expression. Thus, <10% of the transfected cells
cloned from prostate tumors still had inducible expression
of this chemokine and at levels well below that obtained
from the parental line. The failure of transfected cells to
secrete CCL21 was not due to loss of the transgene but
rather methylation of the CMV promoter that drives
expression of this chemokine.
Previous work demonstrated that the chemotactic activ-
ity of CCL21 for DCs and T cells could be used to augment
anti-tumor immune responses [21–23] and all of these
reports indicated that the anti-tumor activity of CCL21 was
mediated by enhancing the infiltration of mature DCs and
CD8
+ T cells to the tumor. These data also suggested that
modification of the TME could lead to effective T cell
priming and the generation of functional anti-tumor effector
cells without interaction of DCs and T cells in lymphoid
organs. Consistent with these studies we found that the
expression of CCL21 in TRAMPC2 TME inhibited tumor
growth (Fig. 4a). We did not detect any major difference in
the composition of the tumor infiltrate in tumors removed
from moribund mice. Differences as a result of CCL21
expression may have existed at earlier times during tumor
growth, a hypothesis that is currently being evaluated. The
inability of CCL21 to induce infiltration of CD8α
+ DCs
may have also contributed to the limited growth inhibition
observed in these studies. The TME represents a potential
rich source of tumor antigen and this DC subset is capable
of cross-presentation to CD8
+ T cells [24].
Although CCL21 is important in recruiting DCs and T
cells and is classified as a CC chemokine (binds to CCR7
receptor), murine CCL21 has been shown to bind to mouse
CXC chemokine receptor CXCR3 [25]. This is a property
that CCL21 shares with two other angiostatic chemokines,
interferon-inducible protein 10 (IP-10) and monokine
induced by interferon-γ (MIG) [26]. CXCL3 is expressed
on human microvascular endothelial cells under normal and
pathological conditions and engagement of this receptor by
these ligands inhibits endothelial cell proliferation in vitro
[27]. Therefore anti-tumor activity of CCL21 can also be
associated with its angiostatic activity through binding to
CXCR3 receptor. Consistent with this view, Arenberg et al.,
showed that injection of CCL21 into the A549 human lung
tumors in the severe combined immunodeficiency (SCID)
mice inhibited tumor growth and reduced metastasis when
the number and size of metastatic loci was compared to
control mice [28]. It has also been shown in some studies
that expression of CCR7 by tumor cells is involved in
directing lymph node metastasis [29]. However, TRAMP
tumor cells do not express CCR7 and therefore other
mechanisms must be responsible for the reproducible
lymph node metastasis of these cells. Potential candidates
include basic fibroblast growth factor (bFGF) and IL-
8 which can promote tumor growth and spontaneous lymph
node metastasis in bladder cancer [30]. Further studies will
be required to identify the signal(s) responsible for
Fig. 4 The CCL21 transgene is retained but the CMV promoter is
methylated in TRAMPC2/TR/CCL21 tumor cells following progres-
sive tumor growth in vivo. a DNA extracted from cloned cell lines
derived from TRAMPC2/TR/CCL21-L2 tumors were tested for the
transgene by PCR using primers specific for CCL21 transgene. Lanes
1–7 represent PCR products obtained when DNA was extracted from
cell lines derived from 7 different TRAMPC2/TR/CCL21-L2 tumors
(Fig. 3a-left panel). PcDNA4/TO/CCL21 plasmid used for transfec-
tion was included as a positive control (lane 8) and mouse DNA was
used as negative control (lane 9). b DNA extracted directly from
TRAMPC2/TR/CCL21-L2 tumors (M1 and M2) and a cell line
derived from tumor M1 (line M1.2, see Fig. 3a-right panel) were
tested for methylation status of CCL21 transgene promoter (CMV).
TO/CCL21 plasmid was used as negative control. Extracted DNAwas
bisulfite treated and then was used in two different PCR reactions
using oligos 1 (directed against a region of the CMV promoter not
containing methylation sites) or oligos 2 (directed against a region of
the CMV promoter which contains methylation sites)
Inhibition of prostate tumor growth by expression of CCL21 65metastatic spread in this tumor model. Inactivation of the
transgene in the prostate TME, limited expression of
CCL21 is sufficient to inhibit prostate tumor growth and
metastatic disease. We previously reported that Fms-like
tyrosine kinase 3 ligand (flt-3-L) therapy of established
TRAMP tumors, in both ectopic and orthotopic settings,
suppressed tumor growth and inhibited metastatic disease
[13, 14]. Although neither of these therapies is curative, the
combination of two treatment strategies may overcome the
immunosuppressive properties of the prostate tumors and be
more effective than either treatment strategy alone. Current
studies are designed to test this paradigm and to identify
promoters that resist inactivation (methylation) in vivo.
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